Rodino-Klapac Louise, HR, D, CSO, reported a transaction classified as withholding at Sarepta Therapeutics, Inc. involving 715.000000 shares for an estimated $74195.55. Reported holdings after the transaction were 67026.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.
Form 4 relationship flags and nearby filing context
Head of R&D, CSO
Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 1, 2024.
Amount of Securities Beneficially Owned includes 111 shares purchased under the Company's registered Employee Stock Purchase Plan on February 28, 2025.
0 other filings
0 recent txs